Porton Pharma Solutions (300363.SZ) subsidiary obtains drug manufacturing license.

Porton Pharma Solutions (300363.SZ) announced that its secondary holding subsidiary, Suzhou Porton Biopharmaceuticals Co., Ltd. (referred to as "Suzhou Porton"), has recently obtained the "Drug Manufacturing License" issued by the Jiangsu Provincial Drug Supervision Administration, which is valid until July 26, 2031. This marks the first time Suzhou Porton has acquired a "Drug Manufacturing License," signifying that Suzhou Porton is now qualified to undertake the compliant production of cell and gene therapy products for commercialization. This qualification will provide a guarantee for Suzhou Porton's future engagement in the commercial production of cell and gene therapy CDMO (Contract Development and Manufacturing Organization), facilitating the development of the company's cell and gene therapy CDMO business.